News & Analysis on Clinical Trial Services & Contract Research And Development
CROs, as well as sponsors, are receptive to, and plan to increase their use of ePRO (electronic patient reported outcomes), according to a survey published Monday from the Tufts Center for the Study of Drug Development.
Industry won’t see much of an initial impact from the US FDA’s newly formed Office of Pharmaceutical Quality, though in a couple of years the agency will have more benchmarks and new technology to find and single out the worst manufacturers.
AMRI has won a contract to develop and manufacture five parenteral generic products for Genovi Pharmaceuticals.
Fareva has added extra micronization capacity citing growing demand and the opportunity to work with customers earlier in the development process as the driver for the investment.
Parexel’s improved book-to-bill ratio is a reassuring sign for the company and the CRO industry as a whole, according to a William Blair analyst.